Tissue transglutaminase (TGase) exhibits both a GTP binding/hydrolytic capability and an enzymatic transamidation activity. Increases in TGase expression and activation often occur in response to stimuli that promote cellular differentiation and apoptosis, yet the signaling mechanisms used by these stimuli to regulate TGase expression and activation and the role of TGase in these cellular processes are not well understood. Retinoic acid (RA) consistently induces TGase expression and activation, and it was shown recently that RA-induced TGase expression was inhibited in NIH3T3 mouse fibroblasts co-stimulated with epidermal growth factor (EGF). Here we investigate whether EGF also antagonized RA-induced TGase expression in breast cancer cells. We found that EGF stimulation affected TGase expression and activation very differently in these cancer cells. Not only did EGF fail to block RA-induced TGase expression, but also EGF alone was sufficient to potently up-regulate TGase expression and activation in SKBR3 cells, as well as MDAMB468 and BT-20 cells. Inhibiting phosphoinositide 3-kinase activity severely diminished the ability of EGF and RA to increase TGase protein levels, whereas a constitutively active form of phosphoinositide 3-kinase potentiated the induction of TGase expression by EGF in SKBR3 cells. Because EGF is an established antiapoptotic factor, we examined whether the protection afforded by EGF was dependent on its ability to up-regulate TGase activity in SKBR3 and BT-20 cells. Exposure of cells to a TGase inhibitor or expression of a dominant-negative form of TGase potently inhibited EGF-mediated protection from doxorubicin-induced apoptosis. Moreover, expression of exogenous TGase in SKBR3 cells mimicked the survival advantage of EGF, suggesting that TGase activation is necessary and sufficient for the antiapoptotic properties of EGF. These findings indicate for the first time that EGF can induce TGase expression and activation in human breast cancer cells and that this contributes to their oncogenic potential by promoting chemoresistance.
Tissue transglutaminase (TGase) 1 is a multifunctional protein with an enzymatic transamidation activity that covalently links proteins to other proteins or polyamines and a GTP binding/GTP hydrolysis cycle similar to other classical G-proteins (1, 2) . The transamidation activity of TGase is highly regulated as underscored by the following two points. First, only a few proteins have been shown to serve as substrates for TGase transamidation in vivo (3) (4) (5) , suggesting that substrate specificity contributes to the overall regulation of this enzymatic reaction. Second, the cross-linking of substrates by TGase occurs only after TGase has proceeded through multiple regulatory events resulting in a TGase species capable of enzymatic activity. One such event involves the ability of TGase to bind and hydrolyze GTP. In vitro studies have demonstrated that the binding of GTP, but not GDP, to TGase inhibits its enzymatic activity (6, 7) . However, the exact mechanism of how GTP binding and hydrolysis regulate the transamidation activity of TGase has yet to be elucidated fully (1, 2, 6 -9) .
Many cell types express TGase at low levels, and increases in TGase expression and enzymatic activity typically occur following exposure to differentiation agents and apoptosis-inducing stimuli (4, 10 -15) . For example, retinoic acid (RA), which has received attention as a cancer therapy because of its growthinhibitory activity, is a consistent inducer of TGase expression and activation (8, 11, (13) (14) (15) . RA-mediated TGase enzymatic activity was shown to be essential for neurite extension in SH-SY5Y cells (11, 13) , whereas blocking RA-stimulated TGase expression in SK-N-BE or U937 cells rescued these cells from RA-induced apoptosis (14, 15) . Conversely, RA-mediated TGase expression was suppressed in fibroblasts expressing an oncogenic form of Ras (16, 17) , implying that retinoid-stimulated TGase expression was inconsistent with the Ras-transformed phenotype. As a result of these and similar findings, such as the proposed use of TGase hypoexpression as a biomarker for prostate cancer (18) , it has become generally accepted that TGase promotes cellular processes that limit cell number. However, recent evidence suggests that TGase may not be detrimental to the growth of all cell types. For instance, exogenous expression of TGase in mouse fibroblasts not only provided a protective effect from serum deprivation-mediated apoptosis but also did not compromise the proliferative capacity of these cells (16) . Furthermore, aberrant TGase expression has been noted in some human brain and breast tumors (19 -21) , but the relevance of TGase overexpression to the progression of these cancers is unknown.
New insights regarding the regulation and function of TGase have come from studies investigating the effect of signaling events on TGase expression and activation (16, 17, 22, 23) . The Ras extracellular signal-regulated kinase (ERK) pathway and the phosphoinositide (PI) 3-kinase-AKT pathway are signal transduction cascades that have received attention for their ability to mediate growth factor-stimulated processes such as inducing cell cycle progression and promoting cell survival (24) . In addition to growth factors like epidermal growth factor (EGF), retinoids can stimulate the activation of these same pathways in certain cell types (22, 25, 26) ; therefore, it was asked whether the ability of RA and EGF to activate the Ras-ERK and PI 3-kinase-AKT pathways influenced TGase expression and activation in the mouse fibroblast cell line NIH3T3 (16) . Stimulation by RA resulted in the activation of PI 3-kinase, which is required for the induction of TGase expression and GTP binding ability. In contrast, stimulation by EGF antagonized the ability of RA to induce TGase expression by activating the Ras-ERK pathway. The use of mouse fibroblasts (NIH3T3 cells) for these studies proved valuable in revealing complex signaling profiles that govern the activation of TGase, yet whether the same signaling events regulate TGase expression and activation in other cell types remains to be established.
We decided to examine the effects of EGF on RA-stimulated TGase expression and activation in the human breast cancer cells. In contrast to NIH3T3 cells, EGF did not inhibit RAinduced TGase expression and activation in SKBR3 cells, nor in MDAMB468 or BT-20 cells. Even more intriguing was that EGF stimulation alone promoted TGase expression and activation more efficiently than RA. Both RA-and EGF-induced TGase expression required PI 3-kinase activity in SKBR3 cells, implicating PI 3-kinase as a common regulator of growth factor-and retinoid-mediated TGase expression in these cells. Inhibiting EGF-stimulated TGase activity resulted in a nearly complete loss of EGF-mediated protection from doxorubicininduced apoptosis in both SKBR3 and BT-20 cells, whereas the ectopic expression of TGase in SKBR3 cells was sufficient to confer resistance from the chemotherapeutic agent. These findings suggest for the first time that EGF-stimulated TGase activity contributes to the oncogenic potential of breast cancer cells by promoting chemoresistance.
EXPERIMENTAL PROCEDURES
Materials-LY294002 and doxorubicin were obtained from Calbiochem, and EGF was from Invitrogen. RA and monodansyl cadaverine (MDC) were purchased from Sigma, and the 5-(biotinamido) pentylamine was from Pierce. The TGase antibody was obtained from Neomarkers; the actin antibody was from Sigma, and the phospho-ERK and -AKT antibodies and cleaved caspase 3 antibody were from Cell Signaling. The EGF receptor and the phospho-EGF receptor antibodies were purchased from Transduction Labs, and the HA and Myc antibodies were from Covance. [␣-32 P]GTP was purchased from PerkinElmer Life Sciences, and all additional material was obtained from Fisher unless stated otherwise.
Cell Culture-NIH3T3 cells were grown in Dulbecco's modified Eagle's medium containing 10% calf serum and 100 units/ml penicillin, and SKBR3, MDAMB231, MDAMB468, and BT-20 cells were grown in RPMI 1640 medium containing 10% fetal bovine serum and 100 units/ml penicillin. The cell lines were maintained in a humidified atmosphere with 5% CO 2 at 37°C. For the various treatments described, the cells were grown to near confluence in medium containing 10% serum, and then medium containing 1% serum or no serum (as indicated under "Results") with 5 M RA and/or 100 ng/ml EGF, Ϯ7 M LY294002 and Ϯ0.2 M doxorubicin, was added for the times indicated under "Results." Cells were rinsed with phosphate-buffered saline and then lysed with cell lysis buffer (10 mM Na 2 HPO 4 , 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% NaF, 1 mM NaVO 4 , 25 mM ␤-glycerophosphoric acid, 100 g/ml phenylmethanesulfonyl fluoride, and 1 g/ml each aprotinin and leupeptin, pH 7.35). The lysates were clarified by centrifugation at 12,000 ϫ g for 10 min at 4°C. Protein concentrations were determined using the Bio-Rad DC protein assay.
Western Blot Analysis-Total cell lysates from each sample were combined with Laemmli sample buffer, boiled, and subjected to SDS-PAGE. The proteins were transferred to nitrocellulose filters and blocked with TBST (20 mM Tris, 137 mM NaCl, pH 7.4, and 0.02% Tween 20) containing 5% nonfat dry milk. The filters were incubated with the various primary antibodies diluted in TBST overnight at 4°C and then washed three times with TBST. To detect the primary antibodies, anti-mouse or anti-rabbit conjugated to horseradish peroxidase (Amersham Biosciences) and diluted 1:5000 in TBST was incubated with the filters for 1 h, followed by three washes with TBST. The protein bands were visualized on x-ray film after exposing the filters to chemiluminescence reagent (ECL, Amersham Biosciences).
Photoaffinity Labeling of TGase-Photoaffinity labeling of TGase was performed by incubating whole cell lysates with 5 Ci of [␣-
32 P]GTP in 50 mM Tris-HCl, pH 7.4, 2 mM EGTA, 1 mM dithiothreitol, 20% (w/v) glycerol, 100 mM NaCl, and 500 M AMP-PNP for 10 min at room temperature. The samples were placed in an ice bath, irradiated with UV light (254 nm) for 15 min, mixed with 5ϫ Laemmli sample buffer, and boiled. SDS-PAGE was performed, followed by transfer to nitrocellulose filters and exposure on x-ray film.
Transamidation Assay-TGase transamidation assays were performed as described previously (27) with slight modifications. 15 g of whole cell extracts were incubated in a buffer containing 2 mM 5-(biotinamido) pentylamine, 40 mM CaCl 2 , and 40 mM dithiothreitol for 20 min. The reaction was stopped by the addition of Laemmli sample buffer followed by boiling. The reactions were then resolved on a 4 -20% gradient SDS-polyacrylamide gel, transferred to nitrocellulose filters, and then blocked overnight with BBST (100 mM boric acid, 20 mM sodium borate, 0.01% SDS, 0.01% Tween 20, and 80 mM NaCl) containing 5% bovine serum albumin. The filters were incubated with horseradish peroxidase-conjugated streptavidin, diluted 1:3000 in BBST for 2 h at room temperature, and then washed five times with BBST. The proteins that incorporated 5-(biotinamido) pentylamine were visualized on x-ray film after exposing the filters to chemiluminescence reagent (ECL, Amersham Biosciences).
Nuclear Condensation or Blebbing Assay-Cells were seeded in 6-well dishes and grown in complete medium for 2 days. The cells were then incubated in medium containing 1% serum Ϯ100 ng/ml EGF and Ϯ10 M MDC for 2 days. The cultures were then incubated with fresh medium containing EGF and MDC and Ϯ0.2 M doxorubicin for an additional 1.5 days and were fixed and stained with 4Ј,6-diamidino-2-phenylindole (2 g/ml) for viewing by fluorescence microscopy. Apoptotic cells were identified by condensed nuclei and/or blebbing.
Cell Growth Assays-Cells were seeded at 1 ϫ 10 5 cells/well and grown in medium containing 0.5% serum Ϯ 5 M RA and Ϯ100 ng/ml EGF. Every 2 days the medium was changed. At 0, 2, 4, and 6 days of treatment, the cells were collected and counted.
RESULTS

EGF Stimulates TGase Expression and Activation in SKBR3
Cells-Previous work on the regulation of TGase activity in NIH3T3 fibroblasts showed that RA-induced TGase expression and activation could be blocked by EGF stimulation (16) . To expand upon this finding, we investigated whether the same interplay that exists between EGF and RA on TGase expression and activation in NIH3T3 cells also occurs in other cell lineages. Because it has been well established that activation of the EGF receptor promotes cell growth and survival and because overexpression of the EGF receptor has been implicated in the progression of several types of human cancers (28), we felt that conducting these experiments in tumor cells that overexpress the EGF receptor had the potential to be interesting. To this end, we chose to study the effects of EGF on RA-induced TGase expression in SKBR3 cells, as well as other human breast cancer cell lines. We felt that SKBR3 cells were particularly well suited for this study because they not only were shown previously to express the EGF receptor at relatively high levels (29, 30) but also were found to be responsive to RA stimulation as indicated by changes in gene transcription following exposure to the retinoid (31) . Fig. 1 (panel labeled ␣EGFR) shows that both NIH3T3 and SKBR3 cells express detectable amounts of the EGF receptor as determined by Western blot analysis. Consistent with reports showing that SKBR3 cells overexpress the EGF receptor (29, 30) , the level of EGF receptor expression in SKBR3 cells was considerably higher than in NIH3T3 cells. We then assayed the ability of EGF to activate its receptor and stimulate intercellular signaling events in the cancer cell line. This was accomplished through the use of antibodies that specifically recognize the activated form of the EGF receptor or AKT and ERK, two signaling molecules consistently activated in an EGF receptor-dependent manner. Treatment of SKBR3 cells with EGF for 5 min resulted in EGF receptor activation (Fig. 1 , panel labeled ␣active EGFR). Coinciding with this activation were increases in the activities of both AKT (Fig. 1 , ␣active AKT) and ERK (Fig. 1, ␣active ERK) , indicating the EGF receptor was capable of signaling in these cells.
We then examined whether RA could up-regulate TGase expression and activation in SKBR3 cells. As shown in our previous work (8, 22) and again here, NIH3T3 cells stimulated with RA for 2 days induced TGase expression ( Fig. 2A, ␣TGase) and GTP binding activity ( Fig. 2A, Fig. 2A,  ␣TGase) . Accompanying this increase in TGase expression was a modest increase in the incorporation of radiolabeled GTP ( Fig. 2A, [␣- 32 P]GTP). The above data establish that SKBR3 cells express relatively high levels of functional EGF receptor and that TGase expression and activation can be augmented by RA stimulation of these cells. Thus, we were in the position to examine the effects of EGF on RA-mediated TGase expression in a cancer cell line that overexpresses the EGF receptor. As shown in Fig. 2A  (panel labeled ␣TGase) , exposure of SKBR3 cells to EGF did not inhibit RA-induced TGase expression, unlike the case of NIH3T3 cells. Perhaps even more interesting, EGF treatment alone was sufficient to up-regulate TGase expression. The EGF-induced TGase was active as indicated by increased GTP binding ( Fig. 2A, [␣- 32 P]GTP) and transamidation activity (Fig.  2B) as readout by the incorporation of 5-(biotinamido) pentylamine into proteins from cell extracts. It is worth noting that although both RA and EGF induced TGase expression in SKBR3 cells, the growth factor was more effective than RA at stimulating the GTP binding and enzymatic activity of TGase. We had earlier obtained evidence in HeLa cells suggesting that the regulated expression of TGase can be uncoupled from the regulation of its GTP binding and transamidation activities (32) . Thus, EGF is apparently able to mediate effectively the regulation of both TGase expression and functional activity in SKBR3 cells.
Because EGF, a known mitogen and survival factor (24, 28) , strongly induced the expression and activation of TGase, a protein that has most often been linked to apoptosis or cell differentiation (3, 10 -15), we next asked how EGF stimulation would affect the growth rate of SKBR3 cells. Fig. 2C shows that SKBR3 cells were able to proliferate in low serum medium, a characteristic often associated with cancer cells. While RA treatment severely diminished the growth of the cancer cell line, EGF treatment did not. The fact that EGF stimulation did not impede the growth of SKBR3 cells, despite strongly activating TGase, indicates that the induction of TGase expression and activation is not necessarily detrimental to the growth rate of SKBR3 cells.
The unique regulation of TGase expression and activation observed in SKBR3 cells was not limited to this cell line, as EGF treatment also enhanced TGase expression in the human breast cancer cell lines MDAMB468 and BT-20 (Fig. 2D) . Moreover, MDAMB231 cells were also found to exhibit a profile of TGase expression and activation that was different from NIH3T3 cells. TGase protein was detected in MDAMB231 cells even in the absence of treatment with RA or EGF ( Fig. 2A,  ␣TGase) . This TGase species displayed GTP binding ( Fig. 2A ,
32 P]GTP) and enzymatic transamidation activity (Fig. 2B ) that was comparable with the TGase activity seen in SKBR3 cells treated with EGF. Growth factor stimulation did not alter the constitutive level of TGase expression or activation in MDAMB231 cells, indicating that EGF-mediated signaling was not a negative regulator of TGase expression in these breast cancer cells as well as in the other cancer cell lines analyzed. The findings associating constitutive or EGF-induced TGase expression and activation in these different breast cancer cells suggest that in addition to being stimulated by factors that induce cell differentiation or apoptosis, TGase activity can also be positively regulated by stimuli associated with cell growth and survival.
PI 3-Kinase Activity Is Essential for EGF-induced TGase Expression in SKBR3 Cells-RA stimulation has been reported to up-regulate the activities of several signaling molecules, including the well established survival factor PI 3-kinase (22, 25) . Recently, it was also shown that PI 3-kinase activity was required for RA to increase TGase expression in NIH3T3 cells (22) , implicating PI 3-kinase as a critical modulator of TGase expression in this cell type. Given that EGF and RA promote TGase expression in SKBR3 cells and that both of these stimuli are known activators of PI 3-kinase, the question arose as to whether the induction of TGase expression by RA and EGF required PI 3-kinase activity. To examine this, we utilized a specific inhibitor of PI 3-kinase known as LY294002. Initially, the effectiveness of the inhibitor at blocking PI 3-kinase activity was tested by comparing the amount of PI 3-kinase activity detected in cells that were incubated with or without LY294002 and then stimulated with EGF. Because the stimulation of AKT phosphorylation by EGF occurs in a PI 3-kinase-dependent fashion (24), we used AKT phosphorylation as a convenient way to read out PI 3-kinase activity. Fig. 3A shows that AKT phosphorylation was stimulated in SKBR3 cells treated with EGF for 5 min. When the cells were preincubated with LY294002, EGF no longer stimulated AKT phosphorylation, suggesting that the inhibitor blocked PI 3-kinase activity. We then assessed whether PI 3-kinase activity was important for the ability of RA or EGF to induce TGase expression in the cancer cell line. LY294002 was nearly as effective at preventing RA-induced TGase expression and GTP binding ability in SKBR3 cells as it was in NIH3T3 cells (Fig. 3B, ␣TGase and   FIG. 1 . EGF receptor activation stimulates intracellular signaling in SKBR3 cells. NIH3T3 cells were serum-starved for 1 day, and SKBR3 cells were serum-starved for 3 days and then were treated with serum-free medium (0) or 100 ng/ml EGF (EGF) for 5 min and lysed. Western blot analysis was performed on the cell extracts to determine the expression levels of the EGF receptor (EGFR) and actin and the activities of the EGF receptor (P-EGFR), AKT (P-AKT), and ERK (P-ERK).
[␣- 32 P]GTP). Blocking PI 3-kinase activation also markedly compromised EGF-stimulated increases in TGase expression, implicating PI 3-kinase activity as a common requirement for growth factor-and retinoid-mediated TGase expression in SKBR3 cells.
To further characterize the role of PI 3-kinase in the regulation of TGase expression in the cancer cell line, we examined whether persistent PI 3-kinase activity was sufficient to induce the expression of TGase. As shown in Fig. 3C , SKBR3 cells transiently transfected with a dominant-active form of PI 3-kinase (a myristoylated form of the p110 catalytic subunit) did not exhibit increased TGase protein levels. However, we did
FIG. 2. EGF potently induces TGase expression and activation in SKBR3
cells. Cells were grown for 2 days in complete medium and then placed in low serum. The following day, cells were left untreated (0), treated with 5 M RA (RA), 100 ng/ml EGF (EGF), or co-treated with 5 M RA and 100 ng/ml EGF (RA/EGF) for 2 days and then lysed. A, the cell extracts were used to determine TGase GTP binding activities (GTP-TGase) using an affinity-labeling assay with radioactive GTP as outlined under "Experimental Procedures." Western blot analysis using TGase and actin antibodies was performed to assess the expression levels of each of these proteins (TGase and actin) . B, the same cell lysates were assayed for TGase transamidation activities as determined by the incorporation of 5-(biotinamido) pentylamine into proteins as described under "Experimental Procedures." The experiments were conducted in triplicate and quantitated, and the values from each experiment were averaged together and plotted. The error bars indicate standard deviations. C, SKBR3 cells were seeded at 1 ϫ 10 5 cells/well, grown in low serum medium Ϯ 5 M RA and Ϯ100 ng/ml EGF for the times indicated, and then counted. The results from three independent growth assays were averaged together and plotted. The error bars indicate standard deviations. D, various breast cancer cell lines were left untreated (0) or were treated with 100 ng/ml EGF (EGF) for 2 days and then lysed. The expression of TGase and actin (TGase and actin) was assessed by Western blot analysis.
find that the induction of TGase expression by EGF was considerably enhanced in cells overexpressing the dominant-active form of PI 3-kinase. These findings indicate that although not sufficient to induce TGase expression on its own, constitutive PI 3-kinase activity potentiated the induction of TGase expression by EGF in SKBR3 cells.
TGase Activation Provides a Protective Effect from Doxorubicin-mediated Apoptosis in Human Breast
Cancer Cells-The activation of TGase has most often been implicated in the induction of apoptosis (3, 10, 14, 15) . On the other hand, recent studies have found TGase activation either to be not directly involved with the programmed cell death process (33) or to provide a protective effect from apoptosis-inducing stresses (8, 34, 35) . We decided to investigate what role TGase played in apoptosis in different human breast cancer cell lines. The apoptotic response of the cancer cells was assayed using the chemotherapeutic agent doxorubicin. As a means to detect cells undergoing apoptosis, immunoblot analysis with an antibody that specifically recognizes the cleaved or activated form of caspase 3 was performed on extracts of SKBR3 and MDAMB231 cells exposed to doxorubicin for increasing lengths of time. Following 24 h of incubation with doxorubicin, activated caspase 3 was easily detected in SKBR3 cells (Fig. 4A,  ␣cleaved caspase 3) . The cleaved caspase 3 levels persisted in these cells for at least another 24 h, indicating that doxorubicin induced a potent and sustained activation of caspase 3 in SKBR3 cells. We confirmed that these cells were undergoing apoptosis by evaluating another set of doxorubicin-treated SKBR3 cells for condensed and/or blebbed nuclei, a morphological feature unique to apoptotic cells. While control cells had low rates of apoptosis, nearly 80% of the cells exposed to doxorubicin displayed nuclear condensation or blebbing (Fig. 4B) .
The apoptotic response of MDAMB231 cells to doxorubicin was also determined. Rather than producing a strong cell death response as in SKBR3 cells, MDAMB231 cells were relatively resistant to the chemotherapy. MDAMB231 cells exposed to doxorubicin failed to induce the cleaved form of caspase 3 to the same extent as SKBR3 cells (Fig. 4A) and showed an apoptotic rate of only 25% (Fig. 4C) . Because chronic TGase activation distinguishes MDAMB231 cells from SKBR3 cells (Fig. 2, A and B) and because MDAMB231 cells are more resistant to doxorubicin-induced apoptosis than SKBR3 cells, the possibility arose that the constitutive TGase activation contributed to the resistance of MDAMB231 cells from doxorubicin-mediated apoptosis. To address this possibility, the cell line was exposed to doxorubicin in the presence of MDC, a competitive inhibitor of TGase-catalyzed transamidation, and the resulting apoptotic rate was determined. As Fig. 4C shows, inhibiting TGase activity with MDC rendered MDAMB231 cells more susceptible to doxorubicin-induced apoptosis as compared with doxorubicin treatment alone.
Based on the data linking TGase to a survival role in MDAMB231 cells, we were particularly interested in assessing whether TGase had a similar function in SKBR3 cells. SKBR3 cells stimulated with EGF for 2 days prior to being exposed to the chemotherapy showed a 50% reduction in the rate of apoptosis of these cells (Fig. 4B) . Because EGF enhances TGase enzymatic activity in this cell line, we then asked what effect inhibiting TGase activation would have on the ability of EGF to inhibit doxorubicin-induced cell death. Incubating SKBR3 cells with MDC nearly completely eliminated the prosurvival effect of EGF from doxorubicin-induced apoptosis, implying that the protective effect afforded by EGF was dependent on the ability of the growth factor to up-regulate TGase expression and activation. This result was not limited to SKBR3 cells as parallel experiments conducted in BT-20 cells, another breast cancer cell line in which EGF stimulates TGase expression (Fig. 2D) , also showed a loss of EGF-mediated protection from doxorubicin-induced cell death when TGase enzymatic activity was blocked (Fig. 4D) . To further verify this result, a genetic approach was also employed. Similar to the findings obtained using MDC, expression of either a GTP binding and transamidation-defective form of TGase (Fig. 5, inset, TGs171e) or a form of TGase that was only transamidation-defective (Fig. 5 , inset, TGc277v) suppressed the protective effect of EGF against doxorubicin-mediated apoptosis in SKBR3 cells (Fig. 5) . In contrast, not only did the overexpression of wild type TGase (Fig. 5, inset, WT TG) potentiate the survival advantage imparted by EGF, but also TGase overexpression alone was sufficient to protect SKBR3 cells from doxorubicin-stimulated apoptosis (Fig. 5) . Therefore, in at least three different breast cancer cell lines, TGase expression and enzymatic transamidation activity elicits an antiapoptotic effect from chemotherapeutically induced cell death. FIG. 3 . LY294002 treatment inhibits the ability of EGF and RA to induce TGase expression and GTP binding activity in SKBR3 cells. Cells were grown to near confluence and then were placed in low serum medium Ϯ 6 M LY294002. A, SKBR3 cells were treated with 100 ng/ml EGF for 5 min, lysed, and then assayed for activated AKT (P-AKT) and actin (actin) by Western blot analysis. LY, LY2940025. B, cells pretreated with or without LY2940025 were then treated Ϯ5 M RA or Ϯ100 ng/ml EGF for 2 additional days before being lysed. The cell extracts were used to determine the expression levels of TGase (TGase) and actin (actin) via Western blot analysis, and TGase GTP binding activity (GTP-TGase) was determined by photoaffinity labeling as outlined under "Experimental Procedures." C, SKBR3 cells transiently transfected with vector only (vector) or a HA-tagged myristoylated form of the catalytic subunit of PI 3-kinase (HA-M-p110) were grown in low serum medium Ϯ 100 ng/ml EGF for 1.5 days and then lysed. Western blot analysis was performed on the cell lysates to assess the expression levels of the HA-tagged PI 3-kinase construct (M-p110), TGase (TGase), and actin (actin).
DISCUSSION
TGase is an unusual dual function enzyme that combines a GTP binding and hydrolysis capability with an enzymatic transamidation activity. Much of the recent interest in TGase stems from the fact that TGase activation has been implicated in the regulation of several, and sometimes opposing, physiological processes (1, 2) . One approach to better characterize the role that TGase has in different cellular events is to elucidate the signaling mechanisms that influence TGase activation. In this study we determined how TGase expression and activation were affected by EGF stimulation in various human breast cancer cell lines. Exposure of different breast cancer cells to EGF resulted in a potent increase in TGase expression and activation (including both GTP binding and enzymatic transamidation activity), and we showed that in SKBR3 cells the up-regulation of TGase expression and activation was dependent on the ability of EGF to stimulate PI 3-kinase activity. The protective effect that EGF provided from doxorubicin-induced apoptosis in SKBR3 cells was severely compromised by expression of a dominant-negative form of TGase, suggesting that EGF-induced TGase activation highlights a novel mechanism associated with chemoresistance by this growth factor.
The finding that EGF induced the expression and activation of TGase in human breast cancer cell lines was quite interesting for two reasons. The first has to do with the fact that TGase expression and activation are not typically up-regulated by growth factors (16, 17) but rather are more uniformly stimulated by differentiation agents (11, 13) , pro-inflammatory cytokines (36) , and cellular stresses (4, 12, 23) . Our data show that EGF appears to be just as effective, if not better, at inducing TGase expression and activation in SKBR3 cells than RA, one of the most consistent and strongest stimulators of TGase expression and activation. This finding suggests that growth factors like EGF might induce TGase expression and activation in some cell lines at least as effectively as extracellular stimuli that trigger differentiation and cell stress responses. In support of this idea, TGase was identified recently in a screen as one of four proteins whose expression was most significantly enhanced by exogenous expression of a constitutively active form of the EGF receptor in a brain tumor cell line (20) .
The second reason that our data linking EGF to the induction of TGase activation in breast cancer cells are interesting is because the data differ from our recent findings in which we determined the effect of EGF stimulation on TGase activation in NIH3T3 mouse fibroblasts (16) . Exposure of NIH3T3 cells to EGF not only failed to induce TGase expression but also blocked the ability of RA to up-regulate TGase expression and activation. How EGF promotes the expression and activation of TGase in some cells and inhibits it in others is not understood and is of specific interest to us. The distinct effects of EGF signaling on TGase expression in these cell lines could be simply because of cell type-specific signaling differences; however, another explanation might involve the deregulated signaling of the EGF receptor in breast cancer cells. For example, in contrast to NIH3T3 cells, SKBR3 cells overexpress the EGF receptor (29, 30) and have impaired rates of EGF receptor endocytosis (29) . As a result, the magnitude and duration of EGF receptor signaling following ligand stimulation are increased in SKBR3 cells as compared with NIH3T3 cells. It is tempting to speculate that the aberrant EGF receptor signaling associated with SKBR3 cells may be an important parameter underlying the ability of EGF to stimulate TGase expression in these cells.
The signaling pathways employed by the EGF receptor for the induction of TGase expression are completely unknown. Here we have begun to delineate these pathways by identifying PI 3-kinase as an important mediator of EGF-induced TGase expression in SKBR3 cells. Inhibiting PI 3-kinase activity strongly antagonized the ability of EGF, as well as RA, to stimulate TGase expression. Moreover, we also found that continuous PI 3-kinase activation alone was not sufficient to stimulate TGase expression in SKBR3 cells but was capable of sensitizing the induction of TGase expression by EGF. Taken together, these findings argue that PI 3-kinase activation serves as an essential and common signaling mechanism regulating the induction and extent of TGase expression and activation by EGF and RA, but these factors must also activate additional pathways to increase TGase expression. Determining the other signaling events that are required for EGF-mediated TGase expression and activation is a focus of our ongoing work. We are investigating currently whether the pathways activated by the small GTP-binding proteins Ras, Rac, Rho, and Cdc42 contribute to the stimulation of TGase expression by EGF. Each of these small GTP-binding proteins is activated by growth factors and has been linked to cell survival (37, 38) , making them potential regulators of TGase.
TGase has been shown to have a role in promoting (3, 14, 15, 23) or inhibiting (8, 23, 34) apoptosis in various types of cells; however, the effect of TGase activity on the viability of human breast cancer cells has not been studied in detail. In this study we have demonstrated that ectopic expression of TGase in SKBR3 cells provides a protective effect from doxorubicin-induced apoptosis, whereas blocking the constitutive TGase activity present in MDAMB231 cells sensitized the cells to doxorubicin-induced cell death. These findings argue strongly for a role for TGase in protecting breast cancer cells from apoptosisinducing stimuli. Moreover, TGase overexpression has been observed in primary human breast and brain tumors (19 -21) , raising the possibility that aberrant TGase activity may be a mechanism used frequently by cancer cells to gain a survival advantage. Although more work is needed to better understand the regulation of TGase expression and activation and to determine how TGase imparts its antiapoptotic effects in breast cancer cells, our findings highlight the importance of TGase for ensuring tumor cell viability and suggest TGase as a potential target for cancer therapy.
